健康经济评估：成本效益阈值和其他决策标准。
Health economic assessment: cost-effectiveness thresholds and other decision criteria.
机构信息
Research Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven. Onderwijs en Navorsing 2, Herestraat 49, 3000 Leuven, Belgium.
出版信息
Int J Environ Res Public Health. 2010 Apr;7(4):1835-40. doi: 10.3390/ijerph7041835. Epub 2010 Apr 20.
Abstract
An article published in this Journal argued that New Zealand does not apply a cost-effectiveness threshold because medicines are funded within a fixed budget and because cost-effectiveness is only one of nine criteria that inform decisions. This Comment has explained that, from a theoretical perspective, the cost-effectiveness threshold model is not inconsistent with these two arguments. The observed annual variation in incremental cost-effectiveness ratios in New Zealand may originate from yearly differences in new medicines that request reimbursement and in the budget size, and from the fact that decision makers take into account other decision criteria in addition to cost-effectiveness.
摘要
本刊发表的一篇文章认为，新西兰没有应用成本效益阈值，因为药品是在固定预算内资助的，并且成本效益只是九个决策标准之一。本评论解释了，从理论角度来看，成本效益阈值模型与这两个论点并不矛盾。新西兰增量成本效益比的年度变化可能源于每年需要报销的新药和预算规模的差异，以及决策者除了成本效益之外还考虑了其他决策标准。
相似文献
1
Health economic assessment: cost-effectiveness thresholds and other decision criteria.健康经济评估：成本效益阈值和其他决策标准。
Int J Environ Res Public Health. 2010 Apr;7(4):1835-40. doi: 10.3390/ijerph7041835. Epub 2010 Apr 20.
2
Comments on "Simoens, S. Health economic assessment: a methodological primer. Int. J. Environ. Res. Public Health 2009, 6, 2950-2966"-New Zealand in fact has no cost-effectiveness threshold.关于“西莫恩斯，S. 健康经济评估：方法学入门。国际环境研究与公共卫生杂志 2009 年，6 月，2950-2966”-事实上，新西兰没有成本效益阈值。
Int J Environ Res Public Health. 2010 Apr;7(4):1831-4. doi: 10.3390/ijerph7041831. Epub 2010 Apr 20.
3
A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].一种用于美国价值评估框架的卫生经济学方法——国际药物经济学与结果研究协会（ISPOR）特别工作组报告的总结与建议[7]
Value Health. 2018 Feb;21(2):161-165. doi: 10.1016/j.jval.2017.12.009.
4
The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.经济证据在加拿大肿瘤学报销决策中的作用：从拉姆达到更远。
Value Health. 2008 Jul-Aug;11(4):771-83. doi: 10.1111/j.1524-4733.2007.00298.x. Epub 2007 Dec 18.
5
A note on the depreciation of the societal perspective in economic evaluation of health care.关于医疗保健经济评估中社会视角贬值的一则注释。
Health Policy. 1995 Jul;33(1):59-66. doi: 10.1016/0168-8510(94)00677-7.
6
Role of budget impact in drug reimbursement decisions.预算影响在药品报销决策中的作用。
J Health Polit Policy Law. 2008 Apr;33(2):225-47. doi: 10.1215/03616878-2007-054.
7
Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.与预算限制和重新分配限制相关的成本效益分析。
Health Policy. 2005 Oct;74(2):146-56. doi: 10.1016/j.healthpol.2004.12.015. Epub 2005 Jan 26.
8
The use of economic evaluations in NHS decision-making: a review and empirical investigation.国民健康服务体系决策中经济评估的应用：一项综述与实证研究
Health Technol Assess. 2008 Apr;12(7):iii, ix-x, 1-175. doi: 10.3310/hta12070.
9
On the role of cost-effectiveness thresholds in healthcare priority setting.关于成本效益阈值在医疗保健优先级设置中的作用。
Int J Technol Assess Health Care. 2021 Jan 25;37:e23. doi: 10.1017/S0266462321000015.
10
Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].目标、预算、阈值与机会成本——一种卫生经济学方法：一份药物经济学与结果研究协会（ISPOR）特别工作组报告[4]
Value Health. 2018 Feb;21(2):140-145. doi: 10.1016/j.jval.2017.12.008.
引用本文的文献
1
Cost-utility analysis of a coadjutant telemedicine intervention for fall prevention in Parkinson's disease.帕金森病跌倒预防辅助远程医疗干预的成本效用分析
Eur J Neurol. 2025 Jan;32(1):e16561. doi: 10.1111/ene.16561.
2
Role of economic evidence in coverage decision-making in South Korea.韩国医保覆盖决策中的经济证据的作用。
PLoS One. 2018 Oct 24;13(10):e0206121. doi: 10.1371/journal.pone.0206121. eCollection 2018.
3
Economic study of the value of expanding HCV treatment capacity in Germany.德国扩大丙型肝炎病毒治疗能力价值的经济学研究
BMJ Open Gastroenterol. 2017 Apr 4;4(1):e000130. doi: 10.1136/bmjgast-2016-000130. eCollection 2017.
4
Preventing postnatal maternal mental health problems using a psychoeducational intervention: the cost-effectiveness of What Were We Thinking.使用心理教育干预预防产后母亲心理健康问题：《我们在想什么》的成本效益分析
BMJ Open. 2016 Nov 18;6(11):e012086. doi: 10.1136/bmjopen-2016-012086.
5
Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective.从澳大利亚视角看依普利酮与常规治疗相比在慢性心力衰竭且纽约心脏协会II级症状患者中的成本效益
Medicine (Baltimore). 2016 May;95(18):e3531. doi: 10.1097/MD.0000000000003531.
6
Protocol for economic evaluation alongside a cluster-randomised controlled trial of a psychoeducational intervention for the primary prevention of postnatal mental health problems in first-time mothers.一项针对首次生育母亲产后心理健康问题一级预防的心理教育干预措施的整群随机对照试验的经济评估方案。
BMJ Open. 2014 Oct 3;4(10):e006226. doi: 10.1136/bmjopen-2014-006226.
7
The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients.Argus II 视网膜假体在色素性视网膜炎患者中的成本效益。
BMC Ophthalmol. 2014 Apr 14;14:49. doi: 10.1186/1471-2415-14-49.
8
Assessment of methodological quality of economic evaluations in belgian drug reimbursement applications.比利时药品报销申请中经济评估方法学质量的评估
PLoS One. 2013 Dec 30;8(12):e85411. doi: 10.1371/journal.pone.0085411. eCollection 2013.
9
Reading a cost-effectiveness or decision analysis study: Five things to consider.阅读成本效益或决策分析研究：需要考虑的五件事。
Neurol Clin Pract. 2013 Oct;3(5):413-420. doi: 10.1212/CPJ.0b013e3182a78fd8.
本文引用的文献
1
Comments on "Simoens, S. Health economic assessment: a methodological primer. Int. J. Environ. Res. Public Health 2009, 6, 2950-2966"-New Zealand in fact has no cost-effectiveness threshold.关于“西莫恩斯，S. 健康经济评估：方法学入门。国际环境研究与公共卫生杂志 2009 年，6 月，2950-2966”-事实上，新西兰没有成本效益阈值。
Int J Environ Res Public Health. 2010 Apr;7(4):1831-4. doi: 10.3390/ijerph7041831. Epub 2010 Apr 20.
2
Health economic assessment: a methodological primer.健康经济评估：方法学入门。
Int J Environ Res Public Health. 2009 Dec;6(12):2950-66. doi: 10.3390/ijerph6122950. Epub 2009 Nov 27.
3
Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.证据与价值：罕见病药物公共报销的要求——肿瘤学案例研究
Can J Clin Pharmacol. 2009 Summer;16(2):e273-81; discussion e282-4. Epub 2009 May 13.
4
Priority setting of health interventions: the need for multi-criteria decision analysis.卫生干预措施的优先级设定：多标准决策分析的必要性。
Cost Eff Resour Alloc. 2006 Aug 21;4:14. doi: 10.1186/1478-7547-4-14.
5
Opportunity costs and uncertainty in the economic evaluation of health care interventions.医疗保健干预措施经济评估中的机会成本与不确定性
Health Econ. 2002 Jan;11(1):23-31. doi: 10.1002/hec.641.
6
What is 'best practice' in health care? State of the art and perspectives in improving the effectiveness and efficiency of the European health care systems.医疗保健中的“最佳实践”是什么？提升欧洲医疗保健系统有效性和效率的最新技术水平与观点。
Health Policy. 2001 Jun;56(3):235-50. doi: 10.1016/s0168-8510(00)00138-x.
Zotero 插件